Kirti Ganorkar, a long-time Sun Pharma veteran, will take over as Managing Director from September 1, succeeding founder Dilip Shanghvi, who remains Executive Chairman. This transition marks the culmination of Sun Pharma's succession plan, as Ganorkar steps into the role amidst a challenging global market.
from Healthcare/Biotech-Industry-Economic...
Sun Pharma gets eight observations from USFDA for Halol plant
Sun Pharma announced that the USFDA issued a Form 483 with eight observations after inspecting its Halol manufacturing plant in Gujarat. The USFDA conducted a Good Manufacturing Practices (GMP) inspection at the facility from June 2-13, 2025. The Form 483, issued at the inspection's conclusion, highlights conditions that may violate the Food, Drug,...
Delhi HC refuses to halt Sun Pharma’s Pruease tables sales over trademark row
The Delhi High Court has denied RSPL Health's petition to stop Sun Pharmaceutical Industries from selling Pruease tablets, a constipation relief medication. RSPL Health, which sells sanitary napkins under the trademark 'Pro-ease,' claimed trademark infringement. The court dismissed the plea, stating that the products have distinct trade channels and...
Sun Pharma appoints Kirti Ganorkar as MD; Dilip Shanghvi to continue as the Executive Chairman of the Board
Sun Pharmaceutical Industries has appointed Kirti Ganorkar as Managing Director, succeeding Dilip Shanghvi, effective September 1. Shanghvi will continue as Executive Chairman, focusing on specialty portfolio and long-term strategy. Additionally, Richard Ascroft will succeed Abhay Gandhi as CEO – North America, reporting to Aalok Shanghvi, who takes...
Bharat Biotech, GSK join hands to develop vaccine for severe diarrhoea
Bharat Biotech and GSK plc have partnered to develop a vaccine for Shigellosis, a severe bacterial diarrhea. The altSonflex1-2-3 vaccine candidate, developed by GSK, will be further developed by Bharat Biotech, including Phase 3 trials and manufacturing. This collaboration aims to address the urgent need for a Shigella vaccine due to rising antimicrobial...
Pharma body opposes entry curbs on medical representatives, seeks rethink
The Indian Pharmaceutical Alliance (IPA) voices concerns over the government's ban on medical representatives in central hospitals, arguing it hinders knowledge dissemination and patient care. IPA urges a structured engagement model, citing potential impacts on pharmaceutical growth, job losses, and the introduction of new therapies. They emphasize...
Niti Aayog may prescribe major revamp of AIIMS Delhi
Niti Aayog is expected to propose a major overhaul of AIIMS Delhi, including expanding its clinical services across the NCR to ease infrastructure pressure and allow doctors to focus more on research. A VK Paul-led committee is preparing a blueprint to reform AIIMS to global standards, with plans to utilize other government or private hospital spaces...
Glenmark to launch DCGI-approved cancer drug in India
Glenmark Pharmaceuticals is set to introduce zanubrutinib, a cancer treatment drug, in India. This follows approval from the Drugs Controller General of India. The drug, branded as Brukinsa, treats five B-cell malignancies. Glenmark anticipates launching Brukinsa soon, in partnership with BeOne Medicines. This launch expands Glenmark's oncology offerings,...
Advent International to acquire stake in Felix Pharmaceuticals
Advent International is set to invest $175 million in Felix Pharmaceuticals, acquiring a significant minority stake. Felix Pharma, a Dublin-based company, specializes in generic animal pharmaceuticals, particularly for companion animals. With 14 USFDA-approved products and a robust pipeline, Felix aims to expand its global presence with Advent's support...
KKR-backed IVI to buy ART Fertility clinics for $450 million
IVI RMA Global, backed by KKR, is poised to acquire ART Fertility Clinics for $400-450 million, marking a significant expansion into India's burgeoning IVF market. This acquisition will add India to IVI RMA's global presence. The deal highlights the ongoing consolidation in the Indian IVF sector, driven by increasing infertility rates and private equity...
One cough too many: India's TB fight isn't quite there yet
Despite India's commitment to eliminate TB by 2025, the nation grapples with a significant burden of drug-resistant cases and underreporting. Stories like Anushka's highlight the challenges in accessing effective treatments and the critical need for improved diagnostics, funding, and equitable care.
from Healthcare/Biotech-Industry-Economic Times...
API prices fall sharply, easing pressure on India's pharmaceutical industry
India's pharmaceutical industry is experiencing relief as active pharmaceutical ingredient (API) prices plummet due to overcapacity and aggressive pricing strategies from Chinese suppliers. Increased domestic API production, driven by government incentives and reduced raw material costs, further contribute to the decline. This trend is expected to...
Dr Reddy’s, Alvotech to co-develop Keytruda biosimilar
Dr. Reddy's Laboratories and Alvotech are collaborating to develop, manufacture, and commercialize a biosimilar version of Keytruda, a highly successful cancer drug. This partnership aims to provide more affordable treatment options globally as Merck's patents begin to expire around 2028. The collaboration will enhance Dr.
from Healthcare/Biotech-Industry-Economic...
Wockhardt eyes USD 7 billion market opportunity for antibiotic Zaynich in US, Europe
Wockhardt's new antibiotic, Zaynich, targeting gram-negative infections, anticipates a significant USD 7 billion market in the US and Europe. Following a successful pre-NDA meeting with the USFDA, the company plans to file for approval this quarter, aiming for a launch in FY27.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/SqXFZtA
via...
Dr Reddy's, Alvotech join hands to develop biosimilar for cancer treatment
Dr. Reddy's Laboratories has partnered with Alvotech to co-develop and commercialize a biosimilar for pembrolizumab (Keytruda), a crucial cancer treatment with USD 29.5 billion in 2024 sales. The collaboration aims to expedite development and broaden global access to this biosimilar. Both companies will share development, manufacturing costs, and commercialization...
Avoid crowded places: Union Health Ministry amid surge in COVID-19 cases
India faces a rise in Covid-19 cases. The Health Ministry advises avoiding crowds and maintaining hygiene. Technical reviews and preparedness measures are underway. Surveillance for ILI and SARI has increased. Testing and genome sequencing are in progress. States are instructed to ensure resource availability. Mock drills are planned to assess oxygen...
Murae Organisor board to consider bonus issue, dividend payout next week
Murae Organisor's board will convene on June 13 to deliberate on a bonus issue of equity shares and dividend payment for FY25. The company is also eyeing strategic business expansion, including investments in agro and distillery sectors. Furthermore, Murae Organisor has set June 11 as the record date for its 1:2 stock split, reporting a revenue of...
IIT Delhi and AIIMS Delhi to establish AI centre for healthcare with Rs 330 crore grant
IIT Delhi and AIIMS Delhi have partnered to establish a Centre of Excellence for Artificial Intelligence in Healthcare (AI-CoE), supported by a ₹330 crore government grant. The centre aims to develop AI-driven solutions to enhance healthcare access and delivery across India, focusing on key national health programs. This initiative seeks to improve...
Ujjain to host Spiritual & Wellness Summit, showcasing India’s holistic future
Ujjain is set to host the Spiritual & Wellness Summit on June 5, drawing spiritual leaders, wellness experts, and policymakers. Madhya Pradesh Chief Minister Mohan Yadav will inaugurate the summit, highlighting Ujjain's spiritual legacy. Panel discussions will explore collaborative frameworks harmonizing traditional health systems with modern wellness...
Biocon gets CDSCO nod for generic diabetes medication
Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Type 2 Diabetes in adults and children over 10. CEO Siddharth Mittal highlighted the importance of this vertically integrated GLP-1 drug in expanding access for diabetes patients in India, where cases are rapidly...
Medical representatives banned from visiting doctors in govt hospitals
The central government has banned medical representatives from directly meeting doctors in government hospitals to curb unethical practices and potential conflicts of interest. This decision aims to ensure doctors dedicate their time to patient care rather than promotional activities. The government encourages digital communication for sharing treatment...
Glenmark’s blood cancer drug ISB 2001 shows promising results in trial
Ichnos Glenmark Innovation's ISB 2001 has shown promising results in treating relapsed or refractory multiple myeloma (RRMM), demonstrating a 79% overall response rate in a Phase 1 study. The drug targets two sites on the tumor cell and engages the body's T-cells, offering hope for patients who have exhausted other treatment options.
from Healthcare/Biotech-Industry-Economic...
Sanofi buys US biopharma group Blueprint in $9.1 billion deal
Sanofi is set to acquire Blueprint Medicines for $9.1 billion, strengthening its immunology portfolio with the addition of Ayvakit/Ayvakyt, a drug for systemic mastocytosis. The acquisition also includes elenestinib and BLU-808, expanding Sanofi's pipeline. Blueprint shareholders will receive $129.00 per share in cash, plus contingent value rights...
Apollo Hospitals plans to sell maternity care arm
Apollo Hospitals Enterprises is planning to divest its maternity and infant care chain, Apollo Cradle and Children's Hospital (ACCHL). Allegro Capital has been appointed to find a buyer for ACCHL, with an estimated valuation of ₹1,000-1,200 crore. The sale process is underway, targeting leading private equity funds amidst a growing mother and child...